New JAK inhibitor pill shows promise for Tough-to-Treat arthritis
NCT ID NCT07452445
First seen Mar 12, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study tests a new daily pill called ivarmacitinib for people with rheumatoid arthritis (RA) who did not get better with standard first treatments. The goal is to see if it can reduce joint pain and swelling and control the disease. About 100 adults with moderate to severe RA will take the drug for 12 weeks, and doctors will check how many achieve at least 20% improvement in symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.